Increasingly complex monoclonal antibody molecules will require the right “tool box” for scaling up manufacturing.
Now that high yields have been achieved for the first generation of monoclonal antibodies, the next challenge will be developing ways to produce larger quantities of even more complex antibody formats. These increasingly complex molecules will require the right “tool box” for scaling up manufacturing.
Read this article in BioPharm International's Outsourcing Resources 2019 eBook.
BioPharm International
eBook: Outsourcing Resources 2019
April 2019
Pages: 16–19
When referring to this article, please cite it as Andy Racher, "Complex and Customized: Manufacturing New Molecular Formats,"BioPharm International's Outsourcing Resources eBook (April 2019).
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.